Aim Schizophrenia is a mental disorder and one of the suspected causes is cytokines. One of them is tumour necrosis factor-alpha (TNF-α). Cytokines have the potential to affect cognitive function. The study aimed to find a correlation of TNF-α level with the Mini-Mental State Examination (MMSE) score in patients with schizophrenia (PwS), and comparing the level of TNF-α levels between PwS and healthy controls. Methods We conducted a cross-sectional analytic study and the study designs were correlation and comparative analysis, i.e. using a Mann-Whitney U test. A total number of 100 subjects were collected, and they were divided into two groups of PwS and control group, respectively. Results The results found that most of the PwS subjects were 39 men (78.0%), while the control group were 28 men (56.%). The differences in TNF-α levels between PwS and control groups were found to be significant p <0.001, there was no significant correlation between TNF-α level and the score of MMSE of the PwS with p = 0.938, with a very weak correlation that was r = -0.011, and a negative correlation direction. Conclusion There was a significant difference between TNF-α level of PwS and control group, i.e. PwS group had lower TNF-α level compared to the control group. The TNF-α level of PwS group had a very weak effect on the cause of cognitive dysfunction in PwS group, yet the higher level of it could reduce MMSE score in PwS group.
Mansur RB, Zugman A, Asevedo EM, Cunha GR, Bressan RA, Brietzke E. Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry Clin Neurosci 2012;66:247–60.
2
Li R, Ma X, Wang G, Yang J, Wang C. Why sex differences in schizophrenia? J Transl Neurosci 2016;1:37–42.
3
Chiang SSW, Riedel M, Gruber R, Müller N, Schwarz M. In vivo type II T-helper cells shift in schizophrenia compared to sex- and age-matched healthy controls. Eur J Psychiatry 2011;25:192–204.
4
Zhu F, Zhang L, Liu F, Wu R, Guo W, Ou J, et al. Altered serum tumor necrosis factor and interleukin-1β in first-episode drug-naïve and chronic schizophrenia. Front Neurosci 2018;12;(296).
5
Boerrigter D, Weickert TW, Lenroot R, O’Donnell M, Galletly C, Liu D, et al. Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. J Neuroinflamm 2017;14:1–15.
6
Lee EE, Hong S, Martin AS, Eyler LT, Jeste DV. Inflammation in schizophrenia: cytokine levels and their relationships to demographic and clinical variables. Am J Geriatr Psychiatry 2017;25:50–61.
7
Ergün S, Yanartas Ö, Kandemir G, Yaman A, Yildiz M, Haklar G, et al. The relationship between psychopathology and cognitive functions with cytokines in clinically stable patients with schizophrenia. Psychiatry Clin Psychopharmacol 2018;28:66–72.
8
Simamora RH, Loebis B, Husada MS. Comparison of serum levels of tumor necrosis factor alpha (TNF-α) in Batak male schizophrenic patients versus healthy controls. Int J Life Sci Scienti Res 2018;4:1652–6.
9
Trovão N, Prata J, VonDoellinger O, Santos S, Barbosa M, Coelho R. Peripheral biomarkers for firstepisode psychosis-opportunities from the neuroinflammatory hypothesis of schizophrenia. Psychiatry Investig 2018;16:177–84.
10
Xu H. Neuroinflammation in schizophrenia focused on the pharmacological and therapeutic evidence. Pharmacol 2015;6:438–53.
11
R TH, M J, SP S, M O, MA S, Y L, et al. Host and environmental factors influencing individual human cytokine responses. Cell 2016;167:1111–24.
12
Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment 2012;2012;(916198).
13
Pollmächer T, Haack M, Schuld A, Reichenberg A, Yirmiya R. Low levels of circulating inflammatory cytokines-do they affect human brain functions? Brain Behav Immun 2002;16:525–32.
14
Hoseth EZ, Ueland T, Dieset I, Birnbaum R, Shin JH, Kleinman JE, et al. A study of TNF pathway activation in schizophrenia and bipolar disorder in plasma and brain tissue. Schizophr Bull 2017;43:881–90.
15
Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease state and inflammation n.d.
16
Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull 2013;39:1174–9.
17
Hennessy E, Gormley S, Lopez-Rodriguez AB, Murray C, Murray C, Cunningham C. Systemic TNF-α produce acute cognitive dysfunction and exaggerated sickness behaviour when superimposed upon progressive neurodegeneration. Brain Behav Immun 2017;59:233–44.
18
Şahin TD, Karson A, Balci F, Yazir Y, Bayramgürler D, Utkan T. TNF-alpha inhibition prevents cognitive decline and maintains hippocampal BDNF levels in the unpredictable chronic mild stress rat model of depression. Behav Brain Res 2015;292:233–40.
19
Belarbi K, Jopson T, Tweedie D, Arellano C, Luo W, Greig NH, et al. TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J Neuroinflamm 2012;9;(23).
20
Thomasy H. Tumor necrosis factor α as a potential mediator of the effects of phosphodiesterase 4B inhibition on cognition after traumatic brain injury. J Neurosci 2016;36:11587–9.
21
Miller BJ, Culpepper N, Rapaport MH, Buckley P. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog Neuropsychopharmacol Biol Psychiatry 2013;42:92–100.
22
Misiak B, Stańczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Schizophr Res 2018;192:16–29.
Gupta S, Kulhara P. What is schizophrenia: a neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis. Indian J Psychiatry 2010;52:21–7.
25
Nawa H, Takahashi M, Paterson PH. Cytokine and growth factor involvement in schizophrenia – support for the developmental model. Mol Psychiatry 2000;5:594–603.
26
Naudin J, Capo C, Giusan B, Mège JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? Schizophr Res 1997;26:227–33.
27
Erbagci AB, Herken H, Köyloüglu O, Yilmaz N, IL-1β TMS, sIL-2R. IL-6, IL-8 and TNF-α in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 2001;10:109–15.
28
Kowalski J, Blada P, Kucia K, Madej A, Herman ZS. Neuroleptics normalize increased release of interleukin-1β and tumor necrosis factor-α from monocytes in schizophrenia. Schizophr Res 2001;50:169–75.
29
Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP, et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 2001;47:13–25.
30
O’Brien SM, Dinan SP, T.G. Increased tumor necrosis factor-alpha concentrations in excacerbations of schizophrenia. Psychiatry Res 2008;160:256–62.
31
Czerski PM, Rybakowski F, Kapelski P, Rybakowski JK, Dmitrzak-Węglarz M, Leszczyńska-Rodziewicz A, et al. Association of tumor necrosis factor – 308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology 2008;57:88–94.
32
M.d.R G-M, J P-M, B L-C, F S-R, P P-M, A O-C, et al. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psychiatric Res 2010;4:441–6.
33
Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Expert Rev Neurother 2007;7:789–96.
Xiu MH, Man L-J, Wang D, Du X, Yin G, Zhang Y, et al. Tumor necrosis factor-alpha-1031T/C polymorphism is associated with cognitive deficits in chronic schizophrenia patients with healthy controls. Am J Med Genet B Neuropsychiatr Genet n.d.;2018;(177).
36
Organization WH. The ICD-10 classification of mental and behavioural disorders. 1992.
37
Folstein M, Folsten S, McHugh P. Mini-mental state: a practical method for grading the cognitive state of patient for the clinician. J Psychiatry Res 1975;12:189–98.
38
Indonesia KP. Modul psikiatri geriatri (Geriatric psychiatry module 2008.
39
Lv MH, Y.L T, Yan SX, Tian L, Chen DC, Tan SP, et al. Decreased serum TNFalpha levels in chronic schizophrenia patients on long-term antipsychotics: correlation with psychopathology and cognition. Psychopharmacol 2015;232:165–72.
40
Kunz M, Ceresér KM, Goi PD, Fries GR, Teixera AL, Fernandes BS, et al. Serum levels of IL-6, IL-10, TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Braz J Psychiatry 2011;33:268–74.
41
Tian L, Tan Y, Chen D, Lv M, Tan S, Soares JC, et al. Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia. vol. 54. 2014.
42
Kubistova A, Horacek J, Novak T. Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr Danub 2012;24:153–6.
43
Hope S, Melle I, Aukrust P, Steen NE, Birkenaes AB, Lorentzen S, et al. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord 2009;11:726–34.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
